Barclays analyst Peter Lawson raised the firm’s price target on Syndax (SNDX) to $22 from $19 and keeps an Overweight rating on the shares. The company’s “softer” Q3 was well telegraphed by management, and the focus can now turn to Q4 and Q1, with expectations for stronger growth, the analyst tells investors in a research note. The firm cites approval in NPM1 and better traction of Niktimvo for the target bump.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax Pharmaceuticals Reports Strong Q3 2025 Growth
- Syndax reports Q3 EPS (70c), consensus (71c)
- Syndax sees operating expense base remaining stable over next few years
- Syndax options imply 10.9% move in share price post-earnings
- Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025